PharmaVentures Completes M&A Deal for Technology in the Stem Cell and Regenerative Medicine Sector

OXFORD, UK, June 30th, 2015

PharmaVentures is pleased to announce that it has acted as advisor to CM Technology Oy (CMT) on its divestment of certain assets to Yokogawa Electric Corporation (Yokogawa). The assets relate to CMT's world leading capabilities in cellular imaging and analysis.

This transaction is the latest in a series of successful global deals in the life science research tools sector for PharmaVentures' clients.

Another successful pharma divestment by PharmaVentures

OXFORD, UK, May 29th, 2015 Pharma

PharmaVentures is pleased to announce that it has acted as advisor to one of the top US pharmaceutical companies in its divestment of one of its manufacturing facilities to a US contract manufacturer. The divestment, completed in mid-May, has led to the protection of hundreds of jobs.

This divestment follows PharmaVentures continued success in M&A including the executing of multiple divestments for several of the largest pharmaceutical companies in the world.

PharmaVentures further strengthens its Business Development team

Oxford, UK. March 4th 2015

Following another year of successful deal making, PharmaVentures is pleased to announce the appointment of Graham Combe who has joined its Business Development team.

PharmaVentures increases life science presence in the USA

OXFORD, UK,February 10th, 2015

PharmaVentures is pleased to announce that it is to increase its life science presence in the North America by establishing a new base in Boston, MA, immediately.

Client News Update: Novartis enters exclusive talks on the potential sale of its UK Horsham site to the University of Brighton.

OXFORD, UK, January 27th, 2015

PharmaVentures is pleased to announce that their client Novartis has entered into exclusive negotiations with the University of Brighton on the purchase of its UK Horsham site announced on the 26th January 2015.

PharmaVentures Advises ESTEVE in Its pharma licensing Deal for E-58425, a New Therapeutic Product for Pain

Pharma licensing agreement OXFORD, UK, January 13th, 2015

PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful pharma licensing agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.

PharmaVentures becomes latest Partner of One Nucleus

Oxford, UK, January 12th 2015

PharmaVentures has become the latest Partner to join forces with One Nucleus. Both PharmaVentures and One Nucleus are committed to playing an active and supportive role in assisting in the success of the life sciences sector nationally and internationally.

 

PharmaVentures Acts As Advisor to Plethora Solutions in deal with Recordati

OXFORD, UK, October 1st, 2014

PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature ejaculation.

PharmaVentures increases its Asia-Pacific presence

OXFORD, UK, September 24th, 2014

PharmaVentures are delighted to announce that Aki von Roy has joined as an Associate, based in Auckland, New Zealand. He has over 30 years experience in Big Pharma and 16 years in biotech. He has been involved in over 18 start-up or merger ventures as director or investor. 

PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease

OXFORD, UK, September 17th, 2014

PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis' unique therapeutic approach, which will be used in the clinical development of potential treatments for Parkinson's disease, delivers GDNF (glial cell-derived neurotrophic factor) precisely to the regions of the brain where it is required via its convection enhanced delivery (CED) technology.

Pages

_

PharmaVentures talks to: